Color Health Genetic Testing: Clinical-Grade Hereditary Cancer Screening With Genetic Counseling Included

Unlike consumer genetics services that test a handful of variants, Color screens the full coding regions of genes linked to hereditary cancer and heart disease, with genetic counseling included in every test. For people with family histories, this distinction could be lifesaving.

Presented By Our Partners

In 2013, Angelina Jolie disclosed that she carried a pathogenic BRCA1 mutation and had undergone a preventive double mastectomy, reducing her breast cancer risk from an estimated 87% to under 5%. The “Angelina effect” drove millions of women to ask their doctors about genetic testing. But a decade later, the vast majority of people who carry actionable hereditary cancer mutations still do not know it. A 2022 systematic review published in Frontiers in Genetics by Shen et al. estimated that 1% to 3% of the general population carries a genetic variant predisposing them to a clinically actionable hereditary disease. The barriers are structural: clinical genetic testing has historically been expensive, difficult to access, and reserved for patients who met narrow family history criteria. Consumer tests like 23andMe expanded access but screen for only a tiny fraction of known pathogenic variants. Color Health was founded to bridge this gap: a clinical-grade genetic testing service that screens the complete coding regions of genes associated with hereditary cancer and cardiovascular disease, includes pre- and post-test genetic counseling, and delivers results that physicians can act on directly.

What Is Color Health Genetic Testing?

Color Health offers clinical-grade genetic testing for hereditary cancer risk and hereditary heart disease risk through an at-home saliva collection kit. The test costs $249 and requires no physician order, though results are delivered with the support of board-certified genetic counselors who help users interpret findings and determine next steps.

The hereditary cancer panel sequences the complete coding regions of genes including BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, APC, MUTYH, PALB2, CHEK2, ATM, and others associated with Lynch syndrome, hereditary breast and ovarian cancer syndrome, and familial adenomatous polyposis. The hereditary heart disease panel covers genes associated with hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, familial hypercholesterolemia, and Long QT syndrome. A pharmacogenomics add-on is also available, testing how genes affect response to certain medications.

The critical distinction between Color and consumer genotyping services is methodology: Color performs next-generation sequencing (NGS) of the entire coding regions of these genes, including deletion/duplication analysis. This means it can detect any pathogenic variant in the tested gene, not just the handful of preselected variants that SNP genotyping arrays like 23andMe assess. For BRCA1/2 alone, there are over 1,000 known pathogenic variants. 23andMe tests for three. Color tests for all of them.

The Science Behind It: Hereditary Cancer Risk and the Case for Comprehensive Screening

Hereditary cancer syndromes account for approximately 5% to 10% of all cancers. The most well-characterized are hereditary breast and ovarian cancer syndrome (HBOC), caused primarily by pathogenic variants in BRCA1 and BRCA2, and Lynch syndrome, caused by variants in mismatch repair genes (MLH1, MSH2, MSH6, PMS2) that dramatically increase risk for colorectal, endometrial, and other cancers.

Women with pathogenic BRCA1 mutations face a 55% to 72% lifetime risk of breast cancer and a 39% to 44% lifetime risk of ovarian cancer, compared to population averages of approximately 13% and 1.2% respectively. Lynch syndrome carriers face up to an 80% lifetime risk of colorectal cancer and up to 60% risk of endometrial cancer, depending on the specific gene and variant involved. These risks are high enough that national guidelines recommend specific surveillance protocols, prophylactic interventions, and treatment modifications for identified carriers.

The Shen et al. 2022 systematic review in Frontiers in Genetics found that the primary barriers to population genetic screening were inadequate knowledge among healthcare providers and perceived limited clinical utility. Critically, the review also found that once individuals were screened, the identified carriers demonstrated high rates of pursuing recommended surveillance and preventive measures. The bottleneck is access and awareness, not willingness to act.

The clinical utility of comprehensive gene sequencing versus limited SNP testing is substantial. A study of clinical BRCA testing found that approximately 50% of pathogenic BRCA variants would be missed by a test that screened only the three Ashkenazi-founder mutations (the same three variants that 23andMe tests). For non-Ashkenazi populations, the miss rate is even higher. This gap between consumer genotyping and clinical sequencing is the core of Color’s value proposition. That is the science. Here is how Color applies it.

What Color Health Does Well

Color’s most important feature is its clinical-grade sequencing methodology. By performing next-generation sequencing across the full coding regions of tested genes, including deletion and duplication analysis, Color detects pathogenic variants that consumer SNP arrays cannot. For hereditary cancer risk assessment specifically, this methodological difference is the difference between a screening test that catches a fraction of carriers and one that catches virtually all of them.

The included genetic counseling distinguishes Color from every consumer-focused competitor. Board-certified genetic counselors are available before and after testing to explain the implications of results, discuss family history context, recommend next steps, and coordinate with the user’s healthcare providers. This counseling layer addresses the interpretation gap that is one of the most significant risks of direct-to-consumer genetic testing: receiving a result you do not have the expertise to contextualize.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Color has built significant partnerships with employers and health systems, making its testing available through corporate wellness programs and institutional screening initiatives. These partnerships have expanded access to clinical-grade genetic testing beyond the traditional model of physician-ordered, insurance-billed testing, lowering barriers for populations that might not otherwise seek or receive hereditary cancer screening. The FDA authorization for specific health reports provides additional regulatory credibility.

Pricing, Access, and Practical Realities

Color Health genetic testing costs $249 as a one-time purchase, which includes the test kit, sequencing, results, and genetic counseling. No subscription is required. No physician order is required for the consumer product, though results are designed to be shared with healthcare providers for clinical action.

Results are typically delivered within 3 to 4 weeks. The testing is performed in a CLIA-certified, CAP-accredited laboratory. Color’s results are formatted as clinical-grade reports that healthcare providers can incorporate directly into medical records and use for clinical decision-making, unlike consumer reports from 23andMe or AncestryDNA that are classified as informational.

Color is not typically listed as HSA or FSA eligible for the consumer-direct product, though employer-sponsored programs may have different arrangements. Insurance coverage varies; Color’s direct pricing of $249 is designed to be accessible regardless of insurance status. For comparison, traditional clinical genetic testing through a hospital genetics clinic can cost $1,000 to $4,000 before insurance.

Who Color Health Is Best For

Color Health is the optimal choice for anyone with a family history of breast, ovarian, colorectal, or endometrial cancer who wants comprehensive hereditary cancer screening. It is strongly recommended for individuals of any ancestry who have not been previously tested with clinical-grade sequencing, as consumer genotyping misses the majority of pathogenic variants. People considering family planning who want to understand their carrier status for hereditary conditions will find Color’s comprehensive panels more thorough than consumer alternatives. Healthcare providers seeking to offer genetic screening to their patient populations can use Color’s institutional programs to expand access.

Those who should consider alternatives include users whose primary interest is ancestry and genealogy, where AncestryDNA or 23andMe provide more relevant features. Anyone seeking biological age measurement needs epigenetic testing (TruDiagnostic, Elysium, GlycanAge), which is an entirely different category. Users who want whole genome sequencing for maximum genetic data should choose Nebula Genomics, though they should understand that WGS data requires separate bioinformatic analysis and does not include the genetic counseling that Color provides. Budget-conscious consumers without specific cancer or cardiac family history may find 23andMe’s broader but shallower approach sufficient for initial screening.

How Color Health Compares

23andMe Health + Ancestry ($229) tests three BRCA variants via SNP genotyping with FDA authorization. Color Health ($249) sequences the full coding regions of BRCA1/2 and dozens of other cancer and cardiac genes with clinical-grade methodology and genetic counseling. For hereditary cancer risk assessment specifically, Color is categorically more comprehensive. The $20 price difference between 23andMe and Color makes Color the clear choice for anyone whose primary concern is cancer risk.

Myriad Genetics, the company behind GeneSight and the original BRCA testing patents, offers clinical hereditary cancer testing through healthcare providers, often at significantly higher list prices that may be partially covered by insurance. Invitae and Ambry Genetics are other clinical-grade genetic testing laboratories that offer comprehensive hereditary cancer panels through physician orders. Color’s direct-to-consumer access and flat $249 pricing differentiate it from these traditional clinical testing pathways.

Among DTC platforms, Color occupies a unique position: clinical-grade methodology, genetic counseling, and direct consumer access at a price comparable to consumer genotyping. No other product combines all three.

Limitations and Open Questions

Color’s gene panels, while comprehensive within the genes they cover, do not test every gene in the genome. Rare hereditary cancer syndromes caused by genes not included on Color’s panels would be missed. Whole genome sequencing (Nebula Genomics) captures more genetic data but lacks the clinical interpretation infrastructure and genetic counseling that Color provides. The ideal comprehensive approach would combine Color’s targeted clinical testing with broader genomic analysis.

Variants of uncertain significance (VUS) are an inherent challenge in clinical genetic testing. When sequencing entire gene regions, laboratories frequently identify variants whose clinical significance has not yet been established. Receiving a VUS result can create anxiety without providing actionable information. Color’s genetic counselors help contextualize VUS findings, but the uncertainty can be psychologically difficult for some users.

The hereditary cancer and cardiac panels cover conditions with high penetrance and established clinical management guidelines. Common, complex diseases (type 2 diabetes, coronary artery disease, most cancers) are influenced by hundreds of common variants, each with small effects, and are not well captured by targeted gene panels. Users should understand that a negative result from Color does not mean absence of cancer risk, only absence of specific high-penetrance hereditary variants.

What This Means for Your Health

Cancer is one of the Four Shadows that Healthcare Discovery‘s longevity framework identifies as the primary chronic disease threats to healthspan. For the 5% to 10% of cancers driven by hereditary mutations, early identification of carrier status is one of the most impactful interventions available in preventive medicine. Identified BRCA carriers can pursue enhanced surveillance (annual MRI, earlier mammography), risk-reducing medications (tamoxifen, aromatase inhibitors), or prophylactic surgery, each of which dramatically reduces cancer-specific mortality. Lynch syndrome carriers can pursue colonoscopy starting at age 20 to 25, aspirin chemoprevention, and other measures that catch colorectal cancer at treatable stages.

The tragedy of hereditary cancer genetics is not the science; the science is mature and the interventions are proven. The tragedy is access. Most carriers remain unidentified because they have never been offered clinical-grade testing. Consumer genotyping has expanded awareness but provides false reassurance to the majority of carriers whose variants are not on the testing array. Color Health directly addresses this gap by making clinical-grade testing accessible at consumer pricing.

Within the Five Pillars framework, genetic screening is upstream of the pillars themselves: it identifies which individuals need more aggressive surveillance and intervention, allowing the pillar-based lifestyle approach to serve as an additional protective layer rather than the only one. The practical recommendation is straightforward: if you have any family history of breast, ovarian, colorectal, or endometrial cancer, Color Health at $249 is the most important health investment in this entire product category. The test takes 15 minutes. The result could change the trajectory of your life.

Frequently Asked Questions

How is Color Health different from 23andMe for cancer screening?
23andMe tests three specific BRCA1/2 variants using SNP genotyping, most relevant to individuals of Ashkenazi Jewish descent. Color Health sequences the complete coding regions of BRCA1, BRCA2, and dozens of other cancer and cardiac genes using next-generation sequencing, detecting any pathogenic variant in the tested genes. Approximately 50% of pathogenic BRCA variants are missed by tests that screen only the three Ashkenazi-founder mutations. Color also includes genetic counseling; 23andMe does not.

Does Color Health require a doctor’s order?
No. Color’s consumer product is available directly without a physician order. Results are delivered through a secure portal with access to board-certified genetic counselors who help interpret findings. However, if a pathogenic variant is identified, Color recommends sharing results with a healthcare provider to discuss clinical management, surveillance protocols, and potential referrals to specialists.

What does Color Health test for beyond BRCA?
Color’s hereditary cancer panel includes genes associated with Lynch syndrome (MLH1, MSH2, MSH6, PMS2), familial adenomatous polyposis (APC, MUTYH), and other hereditary cancer syndromes (PALB2, CHEK2, ATM, and others). The hereditary heart disease panel covers genes for hypertrophic cardiomyopathy, dilated cardiomyopathy, familial hypercholesterolemia, and Long QT syndrome. A pharmacogenomics option is also available.

Is Color Health covered by insurance?
Color’s direct-to-consumer pricing is $249 regardless of insurance status. Some employer-sponsored programs and health system partnerships may offer Color testing at reduced or no cost. Traditional clinical genetic testing through hospital genetics clinics can cost $1,000 to $4,000 before insurance. Color’s flat pricing model is designed to make clinical-grade testing accessible without navigating insurance authorization.

What happens if Color finds a pathogenic variant?
If a pathogenic variant is identified, Color’s genetic counselors provide detailed post-test counseling explaining the clinical significance, recommended surveillance and prevention strategies, and guidance on which family members should consider testing. Results are formatted as clinical-grade reports that healthcare providers can use for medical decision-making. Color can also help coordinate referrals to specialists, including breast surgeons, oncologists, or cardiologists depending on the findings.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.